Quest Partners LLC bought a new stake in Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 26,164 shares of the company’s stock, valued at approximately $162,000.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. National Bank of Canada FI grew its stake in shares of Fulcrum Therapeutics by 869.6% in the second quarter. National Bank of Canada FI now owns 4,460 shares of the company’s stock valued at $28,000 after buying an additional 4,000 shares in the last quarter. Capstone Investment Advisors LLC purchased a new position in shares of Fulcrum Therapeutics in the fourth quarter valued at approximately $68,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Fulcrum Therapeutics by 66.7% in the first quarter. China Universal Asset Management Co. Ltd. now owns 11,916 shares of the company’s stock valued at $112,000 after purchasing an additional 4,766 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Fulcrum Therapeutics during the 1st quarter worth approximately $115,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Fulcrum Therapeutics during the 2nd quarter worth approximately $130,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.
Fulcrum Therapeutics Stock Performance
FULC opened at $3.18 on Monday. Fulcrum Therapeutics, Inc. has a one year low of $2.87 and a one year high of $13.70. The stock has a market capitalization of $197.65 million, a P/E ratio of -1.99 and a beta of 2.23. The business’s 50-day simple moving average is $8.41 and its 200-day simple moving average is $8.26.
Analyst Ratings Changes
FULC has been the topic of a number of recent research reports. Royal Bank of Canada lowered Fulcrum Therapeutics from an “outperform” rating to a “sector perform” rating and cut their price objective for the stock from $15.00 to $4.00 in a research report on Thursday. Stifel Nicolaus cut Fulcrum Therapeutics from a “buy” rating to a “hold” rating and decreased their price objective for the company from $22.00 to $3.00 in a research note on Thursday. Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday. Leerink Partnrs cut shares of Fulcrum Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday. Finally, HC Wainwright lowered shares of Fulcrum Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $17.00 to $4.00 in a report on Friday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to MarketBeat, Fulcrum Therapeutics has a consensus rating of “Hold” and a consensus price target of $9.33.
Read Our Latest Research Report on FULC
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.
Featured Articles
- Five stocks we like better than Fulcrum Therapeutics
- How to Calculate Inflation Rate
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- What Do S&P 500 Stocks Tell Investors About the Market?
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- What is the Euro STOXX 50 Index?
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.